Inflammation is an essential aspect of innate immunity but also contributes to diverse 16 human diseases. Although much is known about the kinases that control inflammatory signaling, 17 less is known about the opposing phosphatases. Here we report that deletion of the gene 18 encoding PH domain Leucine-rich repeat Protein Phosphatase 1 (PHLPP1) protects mice from 19 lethal lipopolysaccharide (LPS) challenge and live Escherichia coli infection. Investigation of 20 PHLPP1 function in macrophages reveals that it controls the magnitude and duration of 21 inflammatory signaling by dephosphorylating the transcription factor STAT1 on Ser727 to 22 inhibit its activity, reduce its promoter residency, and reduce the expression of target genes 23 involved in innate immunity and cytokine signaling. This previously undescribed function of 24 PHLPP1 depends on a bipartite nuclear localization signal in its unique N-terminal extension. 25
inhibit its activity, reduce its promoter residency, and reduce the expression of target genes 23 involved in innate immunity and cytokine signaling. This previously undescribed function of 24 PHLPP1 depends on a bipartite nuclear localization signal in its unique N-terminal extension. 25
Our data support a model in which nuclear PHLPP1 dephosphorylates STAT1 to control the 26 magnitude and duration of inflammatory signaling in macrophages. 27
HIGHLIGHTS 28
 PHLPP1 controls the transcription of genes involved in inflammatory signaling 29  PHLPP1 dephosphorylates STAT1 on Ser727 to reduce its transcriptional activity 30  PHLPP1 has a nuclear localization signal and a nuclear exclusion signal 31  Loss of PHLPP1 protects mice from sepsis-induced death 32
INTRODUCTION 33
Gene expression is an exquisitely regulated process that maintains cellular homeostasis 34 and orchestrates appropriate responses to environmental stimuli such as hormones, cytokines, 35 and pathogenic microbes (Dawson and Kouzarides, 2012; Flavahan et al., 2017) . Homeostatic 36 control of inflammatory genes is particularly relevant to cancer since chronic inflammation 37 promotes tumorigenesis and influences patient response to cancer therapeutics (Coussens and recognition by TLRs, a pro-inflammatory response is initiated that activates the signal-dependent 55
To explore the role of PHLPP1 in acute inflammation, we examined the kinetics and 126 outcome of sepsis-induced death caused by intraperitoneal (i.p.) injection of Gram-negative E. 127 coli bacteria in WT and Phlpp1 -/-mice. Surprisingly, absence of PHLPP1 provided a strong 128 protective effect; at a dose where more than 50% of WT mice died within 12 h of E. coli 129 challenge, 50% of the Phlpp1 -/-mice remained alive after 10 days ( Figure 1A) . Similarly, 130
Phlpp1
-/-mice were protected from toxicity induced by the purified Gram-negative bacterial cell 131 wall component LPS, with nearly half of the Phlpp1 -/-mice alive after 10 days compared to only 132 1 out of 16 of the WT mice ( Figure 1B) . To understand the lower mortality rates in Phlpp1 -/-133 mice, we measured levels of different cytokines in the serum of mice across a time course 134 following LPS injection ( Figure 1C-E) . Serum levels of pro-inflammatory cytokine interleukin 6 135 (IL-6) were significantly increased in WT mice within 5 h of LPS injection, returning to baseline 136 within 12 h ( Figure 1C) . In contrast, the Phlpp1 -/-mice had 2-fold lower IL-6 levels at 5 h post-137 infection, but these levels were sustained for up to 24 h, suggestive of improper resolution of 138 inflammation. Levels of another pro-inflammatory cytokine, IL-1β, were likewise consistently 139 higher in Phlpp1 -/-mice compared with WT mice ( Figure 1D ). By contrast, levels of anti-140 inflammatory cytokine IL-10 did not differ significantly between the WT and Phlpp1 -/-mice 141 ( Figure 1E ). These findings indicate an essential role for PHLPP1 in regulation of the innate 142 immune response at the whole organism level. 143 8
Loss of PHLPP1 results in a increased STAT1-dependent transcription in macrophages 144
Since macrophages are a key cell type involved in the initial response to E. coli infection 145
and LPS challenge, we analyzed the transcriptome of BMDMs isolated from WT or Phlpp1 -/-146 mice before and after stimulation by the major LPS component, Kdo2-Lipid A (KLA), for 1, 6, 147 or 24 h (Figure 2A) . RNA-Seq analysis identified 1,654 mRNA transcripts induced more than 148 two-fold by KLA treatment, with a false discovery rate (FDR) less than 0.05 at any of the time 149 points. Expression of approximately 12% of these genes (199 genes; Table S1 ) was increased in 150 macrophages from Phlpp1 -/-mice compared to those from littermate control WT mice 6 h 151 following KLA treatment; transcript levels of these genes remained significantly elevated (>two-152 fold) 24 h later. Another set of genes exhibited reduced expression 24 h following KLA 153 treatment (144 genes; Table S2 ). Gene ontology analysis revealed that many of the genes whose 154 expression was elevated in the Phlpp1 -/-macrophages are associated with inflammatory 155 signaling: these included genes annotated for their involvement in the innate immune response, 156 cytokine-cytokine receptor interactions, LPS signaling, interferon-response, and tumor 157 necrosis factor (TNF) signaling-dependent pathways ( Figure 2B) . Genes significantly decreased 158 in Phlpp1 -/-compared to WT macrophages were enriched most significantly in nodes related to 159 central carbon metabolism, and to a lesser extent, chronic inflammatory responses and LPS 160 signaling ( Figure 2B) . 161
To gain insight into gene regulatory mechanisms affected by loss of PHLPP1, we 162 performed de novo motif analysis of the promoters of upregulated genes in Phlpp1 -/-163 macrophages using Hypergeometric Optimization of Motif EnRichment (HOMER), a suite of 164 tools for motif discovery and Next Generation Sequencing (NGS) analysis (Heinz et al., 2010) . 165
This algorithm defines motifs that are statistically enriched in a targeted promoter list compared9 to random promoter sequences with comparable GC content. The analysis revealed significant 167 enrichment of ) and IRF (p<10 -9 ) motifs ( Figure 2C ) in the promoters of genes 168 whose expression was statistically increased in Phlpp1 -/-macrophages compared to WT 169 macrophages. Of the 199 genes with elevated expression, 46% of the genes had promoters with a 170 consensus STAT binding motif, 51% had promoters with a potential binding site for IRF family 171 of transcription factors, and 26% had promoters with predicted binding sites for both STAT and 172 IRF ( Figure 2D) . We selected for further analysis three genes whose expression was elevated in 173 the Phlpp1 -/-compared to WT macrophages and which had proximal STAT1 binding motifs in 174 their promoters: Cd69, Ifit2, and Gbp5. Normalized mRNA-Seq data for each of these three 175 genes confirmed elevated mRNA levels in Phlpp1 The finding that Phlpp1 -/-mice are protected from LPS-induced death allowed us to identify 291 PHLPP1 as a physiologically relevant phosphatase in the overall innate immune response. It is 292 likely that this immunoregulatory phenotype reflects roles of PHLPP1 in several immune cell 293 types, and future studies of mice with cell-specific deletions of Phlpp1 will be of great interest. 294
Investigation of Phlpp1
-/-macrophages indicates a significant role in counter-regulation of 295 STAT1-dependent transcription that emerges as a secondary response to TLR4 ligation. Our 296 mechanistic analyses show that PHLPP1 dephosphorylates STAT1 on a key regulatory site to 297 suppress its transcriptional activity towards an array of genes involved in mounting an 298 inflammatory response to IFNγ. Specifically, PHLPP1 directly dephosphorylates Ser727 on 299 STAT1 in vitro and specifically suppresses phosphorylation of Ser727, but not Tyr701, on 300 STAT1 in cells, correlating to decreased transcriptional activity of STAT1 at one of its major 301 binding sites, the GAS promoter. The intrinsic catalytic activity and nuclear localization of 302 PHLPP1 is required for this transcriptional regulation; while the isolated PP2C domain is not 303 efficient in suppressing GAS promoter activity, forcing the PP2C domain into the nucleus is as 304 effective as the full-length phosphatase in controlling transcriptional activity. Nuclear 305 localization of the full-length enzyme is driven by a bipartite NLS we identify in the NTE. 306
Elimination of PHLPP1 results in global changes in LPS-dependent transcriptional regulation, 307 with 20% of the approximately 2,000 genes whose expression changes upon LPS stimulation 308 differing by more than two-fold in BMDMs from Phlpp1 -/-mice compared to WT mice. 309
Phosphorylation of STAT1 on Ser727 has been proposed to occur following the binding of 310 the Tyr-phosphorylated STAT1 dimer to chromatin (Sadzak et al., 2008) . Ser727 311 phosphorylation on the C-terminal transactivation domain of STAT1 is necessary for maximal 312 16 transcriptional activity. Identification of PHLPP1 as a phosphatase that opposes this 313 phosphorylation provides a mechanism to counter-regulate the activity of this key transcription 314 factor. Several lines of evidence suggest that PHLPP1 may be the major phosphatase that 315 controls this regulatory site. First, genetic depletion of PHLPP1 increases both STAT1 Ser727 316 phosphorylation and transcriptional activity at the GAS promoter, whereas PHLPP1 317 overexpression decreases both STAT1 Ser727 phosphorylation and transcriptional activity at the 318 promoter. Second, both the IFNγ-induced phosphorylation of Ser727 and resulting increase in 319 transcriptional activity at the GAS promoter are insensitive to OA, a phosphatase inhibitor that is 320 ineffective towards PP2C family members but highly effective towards the abundant PP2A in affords an efficient mechanism to restrict its activity by directly opposing its phosphorylation in 347 the nucleus (see Figure 8) . 348
The regulation of STAT1 by PHLPP1 occurs in the nucleus, and we identify motifs in the 349 phosphatase that control both the entry into (NLS) and exit from (NES) the nucleus. on both E. coli-induced sepsis and LPS-induced endotoxemia in mice, it is possible that PHLPP1 377 inhibitors could be explored as adjunctive therapies to antibiotics and supportive care of patients 378 with Gram-negative sepsis, a leading cause of mortality in intensive care units. 379 Full-length PHLPP1 was cloned into pCMV 3xFLAG vector (Sigma-Aldrich, E4401). An NLS 392 was cloned to the N-terminus of the PP2C domain of PHLPP1. A double mutant of NLS-PP2C at 393 residues D1210A and D1413A was cloned by site-directed mutagenesis. The HA-tagged 394 PHLPP1 N-terminal extension (PHLPP1 NTE), residues 1-512, was cloned into pcDNA3 vector 395 (Invitrogen). The NLS1 and NLS2 mutations were cloned by site-directed mutagenesis into HA-396 PHLPP1 NTE. The NES from PKI (LALKLALDI) was cloned into the N-terminus of HA-397 PHLPP1 NTE. The PHLPP1 NES mutant was generated by site-directed mutagenesis. 398
EXPERIMENTAL PROCEDURES 380

Materials and Antibodies
Isolation and treatment of macrophages 399
Primary BMDM cells were isolated from male 6-to 8-week-old C57BL/6 mice (Charles River 400 
Chromatin immunoprecipitation 447
ChIP assays were performed as described before (Stender et al., 2017) . Cells were crosslinked 448 with 2 mM disuccinimidyl glutarate for 30 min prior to 10 min treatment with 1% formaldehyde. 449
The antibodies used in these studies were: STAT1 (sc-345, Santa Cruz Biotechnology). 
